These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2016081)

  • 1. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment.
    Timsit J; Chanson P; Harris AG; Grass P; Guillausseau PJ; Warnet A; Lubetzki J
    Horm Metab Res; 1991 Jan; 23(1):48-9. PubMed ID: 2016081
    [No Abstract]   [Full Text] [Related]  

  • 2. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
    Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
    Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience in treating acromegalic patients with long-acting octreotide].
    Szücs N; Mészáros J; Czirják S; Mondok A; Varga I; Gláz E
    Orv Hetil; 2002 May; 143(19 Suppl):1066-70. PubMed ID: 12063862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
    Esposito V; Esposito D; Lo Iudice G
    Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly.
    Gilbert JA; Miell JP; Chambers SM; McGregor AM; Aylwin SJ
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):742-7. PubMed ID: 15943838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacodynamic analysis of octreotide in acromegalic patients.
    Comets E; Mentré F; Grass P; Kawai R; Marbach P; Vonderscher J
    Clin Pharmacol Ther; 2003 Jan; 73(1):95-106. PubMed ID: 12545148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of octreotide in acromegaly on insulin resistance.
    Breidert M; Pinzer T; Wildbrett J; Bornstein SR; Hanefeld M
    Horm Metab Res; 1995 May; 27(5):226-30. PubMed ID: 7642173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
    Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G
    Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    Growth Horm IGF Res; 2005 Jun; 15(3):200-6. PubMed ID: 15935982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide treatment of acromegaly during pregnancy.
    Mikhail N
    Mayo Clin Proc; 2002 Mar; 77(3):297-8. PubMed ID: 11888040
    [No Abstract]   [Full Text] [Related]  

  • 14. [A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
    Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
    Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):640-52. PubMed ID: 2684694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide is effective in acromegaly but often results in cholelithiasis.
    Daughaday WH
    Ann Intern Med; 1990 Feb; 112(3):159-60. PubMed ID: 2404444
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of antibodies against octreotide in two patients with acromegaly.
    Orskov H; Christensen SE; Weeke J; Kaal A; Harris AG
    Clin Endocrinol (Oxf); 1991 May; 34(5):395-8. PubMed ID: 2060149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of gallbladder contractility after withdrawal of long-term octreotide therapy in acromegalic patients.
    Shi YF; Zhu XF; Harris AG; Zhang JX; Deng JY
    Acta Endocrinol (Copenh); 1993 Sep; 129(3):207-12. PubMed ID: 8212985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Octreotide.
    Wass JA; Besser GM
    Lancet; 1992 May; 339(8803):1228. PubMed ID: 1349954
    [No Abstract]   [Full Text] [Related]  

  • 19. Primary medical therapy for acromegaly.
    Freda PU; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3031-3. PubMed ID: 9745396
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypertransferrinemia in acromegaly.
    Misaki M; Takarada Y; Seguchi C
    Horm Metab Res; 1985 Aug; 17(8):425-6. PubMed ID: 3902606
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.